XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.81

0.0%

Nov 24 3:58 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (4920)	11/28/1997 2:32:00 PM
From: Andrew H	Read Replies (1) of 17367

In light of the recent ENMD news, let's not forget that Xoma is a potential player in anti-angiogenesis as well, although they don't seem to be actively pursuing it at the moment. Below is a section I copied from the Xoma website. It may also be helpful to remember that we are entering the seasonally strong period for biotechs. A review of the IXB index will show that there is considerable support in the 310 area. This support has held and it is quite possible we will see a rally from here to new 52 week highs. BTW, the Xoma website mentions that Xoma will be filing an NDA for Mycoprex this year. Does anyone know when this is supposed to happen? Year is running out. >>XOMA scientists found that certain fragments and derivatives of BPI show even greater activity against bacteria and endotoxins, as well as novel properties such as inhibition of blood vessel formation (anti-angiogenesis). A modified recombinant fragment with potent activity (rBPI21), called Neuprex, is now in four different clinical trials (see BPI backgrounder). BPI-derived Peptides XOMA scientists discovered three active areas (functional domains) within the N-terminal fragment of human BPI (the amino-terminal 199 amino acid fragment). XOMA researchers have identified and characterized a number of peptides (small chains of amino acids) derived from these domains that show potential as new pharmaceuticals. XOMA scientists have derived distinct groups of potent peptides from BPI with five classes of bioactivity: antifungal (kills or inhibits fungi) antibacterial (kills or inhibits bacteria) endotoxin neutralizing (neutralizes poison carried by certain bacteria) heparin neutralizing (neutralizes anticoagulant activity of heparin) anti-angiogenic (inhibits growth of new blood vessels) <<

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next